

NIH Public Access

Author Manuscript

Published in final edited form as:

Structure. 2011 June 8; 19(6): 779–789. doi:10.1016/j.str.2011.03.012.

The structure of neurexin 1α reveals features promoting a role as synaptic organizer

Fang Chen^{*}, Vandavasi Venugopal^{*}, Beverly Murray^{*,&}, and Gabby Rudenko^{*,#}

* Life Sciences Institute, University of Michigan, Ann Arbor, Michigan 48109, USA

[#] Dept. of Pharmacology, University of Michigan, Ann Arbor, Michigan 48109, USA

Summary

 α -Neurexins are essential synaptic adhesion molecules implicated in autism spectrum disorder and schizophrenia. The α -neurexin extracellular domain consists of 6 LNS domains interspersed by 3 EGF-like repeats and interacts with many different proteins in the synaptic cleft. To understand how α -neurexins might function as synaptic organizers, we solved the structure of the neurexin 1 α extracellular domain (n1 α) to 2.65 Å. The L-shaped molecule can be divided into a flexible repeat I (LNS1-EGF-A-LNS2), a rigid horseshoe-shaped repeat II (LNS3-EGF-B-LNS4) with structural similarity to so-called reelin repeats, and an extended repeat III (LNS5-EGF-B-LNS6) with controlled flexibility. A 2.95 Å structure of $n1\alpha$ carrying splice insert SS#3 in LNS4 reveals that SS#3 protrudes as a loop and does not alter the rigid arrangement of repeat II. The global architecture imposed by conserved structural features enables α -neurexins to recruit and organize proteins in distinct and variable ways, influenced by splicing, thereby promoting synaptic function.

Introduction

Neurexins are synaptic adhesion molecules recently implicated in neuro-psychiatric diseases including autism spectrum disorder (ASD) and schizophrenia (SZ) (Südhof 2008, Betancur et al. 2009). Neurexins are located predominantly on the pre-synaptic membrane. Their extracellular domains interact with different proteins in the synaptic cleft, while their cytoplasmic tails interact with the pre-synaptic exocytotic machinery. Neurexins play a role in synapse maturation by fine-tuning synaptic properties and regulate synaptic transmission through a 'trans-synaptic dialog' (Südhof 2008, Missler et al. 2003, Kattenstroth et al. 2004, Zhang et al. 2005, Chubykin et al. 2007). When levels of neurexin 1α (or their ligands neuroligins and LRRTMs) are manipulated in animal models, excitatory and inhibitory transmission is altered, a balance that is thought to be disrupted *in vivo* in many neuropsychiatric diseases (Missler et al. 2003, Kattenstroth et al. 2004, Levinson et al. 2005, Varoqueaux et al. 2006, Chubykin et al. 2007, Tabuchi et al. 2007, Hines et al. 2008, Gibson et al. 2009, Etherton et al. 2009, de Wit et al. 2009, Dahlhaus et al. 2010, Blundell et al.

^{© 2011} Elsevier Inc. All rights reserved.

rudenko@umich.edu (734) 615 9323. &present address: Micromyx, Kalamazoo, Michigan 49008

Author contributions: F.C. performed molecular biology, protein purification and crystallization. V.V. performed crystallization, and structure determination of $n1\alpha$ +SS#3. B.M. performed molecular biology. G.R. conceived the research plan, performed protein purification, crystallization, structure determination of $n1\alpha$ and wrote the manuscript.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

2010). Manipulating levels of neurexins and their ligands in animal models also replicates many of the behavioral alterations seen in humans with ASD and SZ (Beglopoulos et al. 2005, Tabuchi et al. 2007, Hines et al. 2008, Jamain et al. 2008, Blundell et al. 2009, Etherton et al. 2009, Blundell et al. 2010, Dahlhaus et al. 2010). Neurexins and their protein partners are now believed to be central components of a synaptic protein network, which underlies a common biological pathway disrupted in many neuro-psychiatric disorders (Guilmatre 2009).

The extracellular domain of neurexin 1α (n1 α) is composed of three neurexin repeats (I, II and III), which each contain the modules LNS-EGF-LNS (Fig. 1a). N1 α binds endogenous ligands including neuroligins, LRRTM family members, neurexophilin, α -dystroglycan and GABA_A-receptors (Südhof 2008, Ko et al. 2009a, de Wit et al. 2009, Zhang et al. 2010, Siddiqui et al. 2010). α -Neurexins also regulate the functionality of certain Ca²⁺-channels, though direct association has not been demonstrated (Missler et al. 2003, Zhang et al. 2005). Recent studies suggest that other, as yet unidentified, proteins interact with a-neurexins as well (Ko et al. 2009b). Neurexins are structurally and functionally diversified through alternative splicing of their mRNAs (Fig. 1a). Potentially, thousands of different neurexin splice forms are produced with different protein partner binding profiles, generating a diverse portfolio of synaptic organizers. N1 α LNS domains contain two β -sheets stacked as a β-sandwich in a jelly-roll fold (Sheckler et al. 2006, Shen et al. 2008) (Fig. 1a). A functional region called the 'hyper-variable surface' is formed by loops that carry splice inserts SS#2, SS#3, and SS#4 and encompasses a Ca²⁺-binding site (experimentally shown for L2, L4, and L6) (Rudenko et al. 1999, Sheckler et al. 2006, Shen et al. 2008) (Fig. 1a). Some, but not all, protein partners interact with the 'hyper-variable surfaces'. Crystal structures show that neuroligins bind to the hyper-variable surface of the LNS domain in n1 β (identical to n1 α L6) by sandwiching the central Ca²⁺-binding site between the two proteins (Araç et al. 2007, Fabrichny et al. 2007, Chen et al. 2008, Leone et al. 2010). LRRTM proteins compete with neuroligins to bind $n1\beta$, suggesting that they share overlapping binding sites (Ko et al. 2009a, Siddiqui et al. 2010). α-Dystroglycan binds the hyper-variable surface of L2 and its association is disrupted by destroying the Ca^{2+} -binding site; α -dystroglycan also binds to the hyper-variable surface of L6 and is competed by exogenous α -latrotoxin, another ligand for L6 (Sugita et al. 2001). Single LNS domains can support ligand binding; binding of some, but not all, protein partners is regulated by alternative splice inserts and requires Ca^{2+} .

While isolated neurexin LNS domains have been extensively characterized, high resolution information on their arrangement in the full-length $n1\alpha$ extracellular domain is not known, though a recent study using electron microscopy has revealed a low resolution model of $n1\alpha$ (Comoletti et al. 2010). The global organization and conformational freedom between modules in the ectodomain of α -neurexins likely determines the ability of this family of proteins to organize protein partners in the synaptic cleft. To gain insight into $n1\alpha$ structure-function relationships, we solved the structure of bovine $n1\alpha$ by x-ray crystallography to a resolution of 2.65 Å and $n1\alpha$ +SS#3 to 2.95 Å. The crystal structure of $n1\alpha$ reveals an L-shaped molecule. The modules are tethered together in flexible and rigid arrangements encoded by characteristic structural features. Neurexin repeat I is flexible, repeat II adopts a horseshoe-shaped structure similar to reelin repeats, and repeat III adopts an extended arrangement with a putative hinge between L5 and EGF-C. The architecture of $n1\alpha$ is highly suited for a synaptic organizer that arranges different proteins into large macromolecule complexes in order to promote synaptic maturation and transmission efficiency.

Results

Overall shape of $n1\alpha$

N1 α (modules L1-L6, Leu³¹-...-Ser¹³³⁹) is found as a monomer in the crystal structure with an elongated L-shape (Fig. 1b). Continuous electron density is visible for L2, L3, EGF-B, L4, L5, EGF-C and L6 (residues Glu²⁸¹-Val¹³³⁷), including interconnecting residues. L2 through L5 form a long rod-shaped assembly (the 'back' of the 'L'). EGF-C and L6 form a shorter assembly (the 'foot' of the 'L'). The dimensions of the L2–L6 array are ca. 137 Å \times $100 \text{ Å} \times 59 \text{ Å}$. The two crystallographically independent copies of n1a in the asymmetric unit (space group P1) show an identical arrangement of modules (rmsd 0.295 Å for 1003 C^{α} pairs), suggesting their molecular organization is an intrinsic property. N1 α appears increasingly flexible towards its N-terminus. L2 ($B_{average}$ 118.2 Å²) displays more thermal motion than its C-terminal neighbors L3 ($B_{average}$ 83.2 Å²), L4 ($B_{average}$ 31.8 Å²), L5 $(B_{average} 26.9 \text{ Å}^2)$, and L6 $(B_{average} 68.9 \text{ Å}^2)$ (as calculated by TLSANL (CCP4, 1994)). In addition, unlike for the rest of the molecule, the electron density for L2 and the concave β sheet of L3 largely does not resolve the individual β strands, though it clearly reveals the β sheets. No electron density is observed for L1 and EGF-A, though present in the crystal, suggesting that these N-terminal modules are disordered and can adopt multiple conformations. Thus, the crystal structure of $n1\alpha$ reveals 7 out of 9 modules (1003 residues per molecule) organized in an L-shaped assembly. Prior to examining the architecture of $n1\alpha$, and its impact on $n1\alpha$ function, the crystal contacts were analyzed (Supplemental Material, Fig. S1).

Modules of n1a

The individual modules of $n1\alpha$ display striking structural features that appear to have evolved to maintain the global architecture of the extracellular domain. Firstly, though neurexin LNS domains share a common jellyroll fold, characteristic loops extend from their β -sheets. Loop β 11- β 12 ranges from a short 10 residue loop in L6 to a long 16 and 22 residue loop in L3 and L5 with helical content, and fills the concave β -sheet in different ways (Fig. 1b, Fig. 2a). Loop β 4- β 5 of the hyper-variable surface is quite short, just 4 to 6 residues, except in L3 where it spans 18 residues (Fig. 2a). Secondly, in L2, L3, L4, and L5, but not the terminal L6, a cysteine is located just before the polypeptide chain continues on into the next module. These cysteine residues engage in a disulfide bond with a preceding cysteine located on or near strand β 12, one of the last strands in the LNS domain fold (L2: Cys⁴⁴⁴-Cys⁴⁸⁰; L3: Cys⁶⁵⁰-Cys⁶⁷⁹; L4: Cys⁸⁹⁰-Cys⁸⁹⁸; L5: Cys¹⁰⁵⁹-Cys¹⁰⁸⁷). The disulfide bonds rigidly define each module from the interconnecting linker residues and module that follows. Thirdly, the EGF-like repeats B and C are structurally very similar to each other (1.0 Å rmsd for 35 matched C^{α}-atoms), even though they share only 34 % sequence identity (13 out of 38 residues). EGF-B and C both consist of 2 β -strands and loops held together by 3 disulfide bonds (connectivity C1-C3, C2-C4 and C5-C6). Their close structural similarity suggests that these modules are compact, very well-ordered domains that preserve their shape.

Organization of n1α

L2, L3, EGF-B, L4 and L5 form a rod-shaped array by packing sequentially against each other via extensive interdomain interactions. The β -sandwiches of L2, L3, L4, and L5 arrange so that the concave sheet of a preceding LNS domain interacts with the convex sheet of the next LNS domain (Fig. 1b). Loop β 11- β 12 that fills the concave β -sheet and in many structurally related legume lectins forms part of a carbohydrate binding site (Loris et al. 2002), plays an important role in mediating interactions between the concatenated LNS domains (Fig. 1b, Fig. 2a). Loop β 11- β 12 of L2 docks on L3 contacting central β -strands of its convex sheet (β 3, β 8) and the linker between L3 and EGF-B, (see Fig. 1a for

nomenclature). Loop $\beta 11$ - $\beta 12$ of L3, in turn, docks on central β -strands of the convex β sheet of L4. Finally, the base of loop $\beta 11$ - $\beta 12$ of L4 docks on L5 contacting central β strands of the convex sheet of L5, though this interface is more complex and involves additional strands and loops of L4. Remarkably, L6 breaks away from the rod-like assembly, and veers off at ca. 75° angle mediated by EGF-C (Fig. 1b).

Although the protein sequence of $n1\alpha$ can be divided up in three repeats (I, II and III) (Fig. 1a), the spatial organizations of these repeats are dramatically different. The L1-EGF-A-L2 repeat appears flexible, as L1 and EGF-A are not visible in the crystal structure. L3-EGF-B-L4 adopts a globular horseshoe-shaped structure and L5-EGF-C-L6 forms an extended array. The compact EGF-like repeats play a crucial role in determining the different structural arrangements of the neurexin repeats and the overall shape of the $n1\alpha$ extracellular domain.

In L3-EGF-B-L4, EGF-B spans the top of the LNS domain pair providing extensive interactions to both (Fig. 2b, details in legend and summarized below). EGF-B interacts with loops connecting the convex and concave sheets of L3, and β -strands from the convex β sheet of L3. EGF-B contacts β -strands from the convex β -sheet of L4, loop β 12- β 13 that contains helix α 1, and the linker between EGF-B and L4. At the bottom of the L3–L4 pair, the long loop β 4- β 5 that is present only in L3 (refer back to Fig. 2a) arcs over and binds to the 'hyper-variable surface' of L4. Lys⁵³⁸ at the tip of this loop interacts with the side chain of Asp⁷⁷² (loop β 4- β 5) and the backbone carbonyl of Leu⁷⁸⁹ (loop β 6- β 7), two key residues of the Ca²⁺-binding site in L4 (Fig. 2b). This site not only binds Ca²⁺-ions, but also competing positively charged amino-groups (Shen et al. 2008). Remarkably, L3-EGF-B-L4 resembles the jellyroll-EGF-jellyroll arrangement found in so-called 'reelin repeats' of reelin (Fig. 2c), a protein that directs neuronal migration during cortical development and is implicated in neuro-psychiatric disorders (Knuesel 2010, Yasui et al. 2010). Furthermore, the reelin-repeat R6 binds the LA1 module of one of its receptors, the apoE receptor 2, by exploiting a binding site that coincides structurally with the hyper-variable surface of L4 (Fig. 2c).

In L5-EGF-C-L6, EGF-C separates L5 from L6 (Fig. 3). EGF-C interacts with L5 in a fundamentally different way compared to L6, suggesting a structural mechanism has evolved to support neurexin function. EGF-C docks onto the terminal residues of the L5 polypeptide chain (Glu¹⁰⁸⁴ from strand β 14, Gly¹⁰⁸⁶, and its final residue Cys¹⁰⁸⁷). A very short 'hinge' connects L5 and EGF-C (Glu¹⁰⁸⁸-Gly¹⁰⁸⁹). The bulky side chains Arg¹⁰⁸⁵ and Trp¹¹⁰⁹ pack on one side of the hinge, Glu¹⁰⁸⁴ and Lys⁹¹⁷ (that form a salt bridge together) as well as Pro¹⁰⁹⁰ pack on the other side (Fig. 3). These residues likely limit the conformational freedom of the hinge. The hinge is further delineated by residues on either side in the polypeptide sequence: Cys¹⁰⁸⁷-**Glu¹⁰⁸⁸-Gly¹⁰⁸⁹**-Pro¹⁰⁹⁰-Ser¹⁰⁹¹. At one end, the disulfide bond between Cys¹⁰⁸⁷ and Cys¹⁰⁵⁹ covalently restricts motion. At the other end, Pro¹⁰⁹⁰ restricts the polypeptide backbone conformational freedom through its covalent interaction with main chain atoms, while Ser¹⁰⁹¹ and subsequent residues are buried in EGF-C. L6 makes no direct interactions with L5 or the rest of the molecule, other than with the preceding EGF-C. Unlike the interaction between L5 and EGF-C, the interaction between EGF-C and L6 is extensive suggesting that the orientation between EGF-C and L6 is fixed (Fig. 3). The hinge in neurexin repeat III suggests that the 'foot' of the L-shape (EGF-C-L6) can pivot with respect to the 'back' of the L-shape (L2–L5), though the range of motion is likely limited by the residues that pack on either side of the hinge.

N1α+SS#3

The remarkable horseshoe-shaped arrangement of L3-EGF-B-L4 and its similarity to reelin repeats prompted further investigation. The extra long loop β 4- β 5 from L3 that extends its

Structure. Author manuscript; available in PMC 2012 June 8.

tip into the Ca²⁺-binding site of L4 also docks close to the insertion site for splice insert SS#3 (for which no function is known yet). To answer the question if SS#3, which replaces Gly⁷⁹⁰ with a ten amino acid splice insert Asp⁷⁹⁰-Ser⁷⁹⁹ (refer back to Fig. 1a, Fig. 2b) changes the domain organization of L3-EGF-B-L4, we solved the structure of n1 α +SS#3 to a resolution of 2.95 Å. L3-EGF-B-L4 with and without SS#3 superimpose within 0.27 Å for 414 C $^{\alpha}$ -atoms, indicating that SS#3 does not alter the arrangement of the modules (Fig. 4a). Both SS#3 as well as loop β 6- β 7 that hosts the splice insert are clearly visible in the electron density with the exception of a gap corresponding to Cys⁷⁹⁶-Asn⁷⁹⁷-Ser⁷⁹⁸-Ser⁷⁹⁹ of SS#3 (Fig. 4b, Fig. S2). SS#3 extends loop β 6- β 7 out into solution. A salt bridge forms between Arg⁷⁹³ of SS#3 and Asp⁸⁴⁵ of loop β 10- β 11 (Fig. 4c). Cys⁷⁹¹ and Cys⁷⁹⁶ of SS#3 do not engage in a disulfide bridge. The presence of SS#3 does not rearrange the Ca²⁺-binding site of L4 significantly (i.e. the side chain of Asp⁷⁷² and the backbone carbonyls of Arg⁸⁴⁸ and Leu⁷⁸⁹, the latter which is directly adjacent to the splice insert site). Strikingly, the presence of SS#3 does not prevent loop β 4- β 5 of L3 from binding to the hyper-variable surface of L4, and Lys⁵³⁸ is again found blocking the Ca²⁺-binding site of L4 (Fig. 4c). This suggests that the organization of repeat II is an intrinsic property of n1 α that is tied to α -neurexin function.

Discussion

Structure-function relationships of n1a

The remarkable shape of $n1\alpha$ is produced by interplay between structural elements within individual modules and interactions between modules leading to neurexin repeats with very different conformational arrangements and freedoms. The striking structural features that promote this architecture also suggest that the global organization of α -neurexins is fundamentally important for their function as synaptic organizers.

Before evaluating potential structure-function relationships, we assessed whether the crystal structure likely reflects the conformation of $n1\alpha$ in the synaptic cleft.

Does neurexin repeat II form a rigid core? L3-EGF-B-L4 forms the largest intramolecular interface in n1a, burying 2893.3 Å² (1386 Å² between L3 and L4, 870 Å² between L3 and EGF-B, and 637 Å² between EGF-B and L4). SS#3 does not disturb the organization of this repeat, nor prevent loop β 4- β 5 of L3 from inserting into the hyper-variable surface of L4. All mammalian α -neurexin genes share this long loop β 4- β 5 in L3, and a lysine or arginine residue is found at position Lys⁵³⁸ in fourteen mammalian n1 α and n3 α sequences, though ambiguous sequence alignments prevent an analogous residue from being identified in n2a. Reelin repeats show a similar spatial arrangement to neurexin repeat II, though they are further assembled into rod-shaped, linear assemblies, unlike $n1\alpha$ (Fig. 2c, Nogi et al. 2006, Yasui et al. 2007). Both $n1\alpha$ neurexin repeat II and reelin repeat R6 use a lysine residue at the hyper-variable surface (or its structural counterpart) to interact with a protein surface. In $n1\alpha$, Lys⁵³⁸ interacts with Asp⁷⁷² of L4 likely stabilizing neurexin repeat II. In reelin repeat R6, a lysine residue from jelly-roll L1 interacts with a protein partner (LA1 of the apoE receptor 2) via aspartate residues surrounding the LA1 Ca²⁺-binding site (Yasui et al. 2010, Fig. 2c). The situation is not completely analogous, because in n1a, Lys⁵³⁸ blocks the Ca²⁺binding site of L4, whereas in reelin, Lys²⁴⁶⁷ likely requires the Ca²⁺-ion in LA1 to arrange the acidic residue cluster for interaction (Yasui et al. 2010). Nonetheless, the extensive buried surface, the conserved key structural features, undisturbed even by SS#3, and the structural similarity to reelin repeats all suggest that the horse-shoe shaped conformation of L3-EGF-B-L4 is an intrinsic property of the $n1\alpha$ architecture.

Does EGF-C keep L5 and L6 separated at a discrete distance? Though the interface between EGF-C and L6 (990 Å²) is smaller than that buried in the L3-EGF-B-L4 horseshoe, EGF-C likely packs solidly against L6. Its buried surface is on the same scale as that between L2

and L3 (994 Å²), L4 and L5 (1107 Å²), the direct interaction between L3 and L4 (1386 Å²), and the interaction site between reelin R6 and apoE receptor 2 LA1 (~ 700 Å²) with a reported affinity of ~100 nM (Yasui et al. 2010, Fig. 2c). In contrast, the buried surface between L5 and EGF-C is much smaller (289 Å²). Key structural features are identical in almost all 22 sequences from mammalian α -neurexin genes 1, 2 and 3, namely: the hinge residues (Glu¹⁰⁸⁸ and Gly¹⁰⁸⁹), stretches of 7 residues N- and C-terminal to the hinge, and the bulky side chains that pack spatially around the hinge. This suggests that neurexin repeat III enables the rigid EGF-C-L6 assembly to pivot with respect to the rest of the molecule to some (limited) extent.

Are the buried surfaces between modules in the $n1\alpha$ L2–L6 assembly true biological interfaces? Except for one, all the interfaces classify as relatively small biological interfaces (or very large crystal contacts) (see Supplemental Material). However, current methodologies do not accurately discriminate biological interfaces from fortuitous crystal contacts in crystal structures of proteins containing covalently connected modules, like $n1\alpha$, because the steric and entropic contributions imparted by linking modules is not accounted for. Analysis of 22 mammalian α -neurexin sequences shows that almost 80% of all interface residues are either conserved or semi-conserved, and of these, ca. 75% of the Tyr, His, Phe, Trp, Leu, Ile, Val, Met, and Arg residues (residues that are often found at biological contacts (Lo Conte et al. 1999)). Therefore, while the sizes of the buried surfaces between modules in $n1\alpha$ do not unambiguously prove that these interfaces exist in solution, they are large enough and share high enough sequence conservation to indicate they form and that the organization of $n1\alpha$ in the crystal structure likely represents a physiologically relevant conformation.

The shape of $n1\alpha$ shows similarities with molecular envelopes of $n1\alpha$ produced recently by electron microscopy (EM). N1 α was visualized as a Y-shape. L1–L4 were assigned to the long base of the Y, while L5–L6 were assigned to the two arms of the Y (Comoletti et al. 2010). Two regions of flexibility were pinpointed, one between EGF-A and L2 and a second between L5 and L6. The resolution of the EM data did not permit the orientation of the LNS domains to be determined or the position of the EGF-like repeats, thereby limiting further comparison. Nevertheless, the global architecture of $n1\alpha$, i.e. an elongated molecule with L6 veering spatially away from the L2–L5 array, is consistent between the EM and crystallographic studies suggesting it is a physiological feature.

Functional consequences of the $n1\alpha$ architecture

The domain arrangement of $n1\alpha$ has fundamental consequences for α -neurexin function. The hyper-variable surfaces of L2, L3, L4, L5, and L6 line up on one side of the molecule (Fig. 5a). Because these surfaces are putative binding sites for protein partners (discussed in the Introduction), interacting ligands would assemble on just one side of the extracellular domain, a feature that would facilitate pre-synaptically tethered $n1\alpha$ to recruit multiple partners exposed on the opposing post-synaptic membrane. The n1a arrangement also suggests that multiple modes of protein partner recognition are possible. Ligands interacting with different single LNS domains could be recruited simultaneously by α -neurexins and spatially organized into large macromolecular complexes in the synaptic cleft (Fig. 5b). Protein partners might also interact with two LNS domains (Fig. 5c). Though it is not known how multiple domains of $n1\alpha$ might interact with α -dystroglycan, the structurally related laminin α2 LG4–LG5 tandem binds α-dystroglycan using surfaces that surround a Ca²⁺binding site on each module, analogous to the Ca²⁺-binding sites found at neurexin hypervariable surfaces. Although the two LG domains adopt a fixed V-shape not seen in n1a, their arrangement constrains the putative α -dystroglycan binding surfaces to the same side of the molecule at the tips of the V (Tisi et al. 2000). Likewise, a protein partner interacting with neurexin L2 and L3, or L3 and L4, would subject itself to the spatial constraints

imposed by $n l \alpha$. In contrast, proteins interacting with L1 and L2, or L5 and L6 would either need to be flexible themselves or rigid molecules that imposed their own molecular architecture on $n l \alpha$. Lastly, large protein partners might contact more than two adjacent or non-adjacent $n l \alpha$ modules, enabling multiple splice inserts in $n l \alpha$ to potentially modulate protein partner binding and recognition (Fig. 5d). Molecular recognition would be influenced by the rigid and flexible connections within the $n l \alpha$ architecture. The relatively large distances between the splice insert sites (> 26 Å) and the relatively short stretches of polypeptide added (< 30 a.a.) suggest that it is unlikely that splice inserts or insert sites end up directly side-by-side each other. However, a portfolio of different composite binding sites could be formed (like mosaics made up of varying pieces) as a function of the different splice inserts present or absent (Fig. 5d).

With the different binding modes in mind, we modeled the interaction between $n1\alpha$ and neuroligin 1 (NL1), using the structure of the n1 β :NL1 complex as a guide (Araç et al. 2007, Chen et al. 2008). Like neurexins, the family of post-synaptic adhesion molecules, neuroligins, is diversified through alternative splicing at a Site A (which can carry ca. 20 a.a. inserts) and in NL1 also at a Site B (that can carry a 9 a.a. insert) (Südhof 2008). Though n1a appears to bind NL2 preferentially over NL1, NL3 or NL4 (Kang et al. 2008, suggested by Chih et al. 2006), subsequent reports have shown that $n1\alpha$ also binds NL1 if the Site B insert is absent (Boucard et al. 2005, Ko et al. 2009a, Siddiqui et al. 2010, Comoletti et al. 2010, Reissner et al. 2008). Superimposition of $n1\alpha$ L6 on the identical domain of $n1\beta$ of the n1 β :NL1 complex reveals the spatial location of the n1 α specific modules with respect to NL1. The docking studies show that when L6 binds NL1, EGF-C functions as a spacer, placing the L2-L5 assembly alongside each NL1 subunit of the dimer (Fig. 6). In the n1α:NL1 model, Site B of NL1 is close to the interface between L6 and NL1, and Site A of NL1 in close to L3 and L4 (Fig. 6). The hinge between L5 and EGF-C would permit optimal alignment of L3 and/or L4 with NL1. Our docking studies therefore suggest that it is possible for Site B in NL1 to cooperate with SS#4 of L6 in $n1\alpha$ (as it does in $n1\beta$, Arac et al. 2007, Chen et al. 2008) following the concept of a splice code centered around Site B and SS#4 that governs the interactions between neurexins and neuroligins (Südhof 2008). In addition, it is possible that Site A in neuroligins cooperates with SS#3 of L4. If true, interaction between Site B and SS#4 would constitute one part of the splice code, and Site A and SS#3 another for regulating binding between α -neurexins and neuroligins.

Our model of the $n1\alpha$:NL1 complex is consistent with biochemical data describing the interaction of $n1\alpha$ with different partners.

Neuroligins—Because L6 protrudes as an isolated domain from $n1\alpha$ extending its hypervariable surface out to the solvent (Fig. 1b, Fig. 6), it is likely that the binding mode between $n1\beta$ and neuroligins is largely preserved in the interactions between L6 of $n1\alpha$ and neuroligins. N1B and NL1 splice forms bind with nanomolar affinity (ca. 10-95 nM, Comoletti et al. 2006, Araç et al. 2007, Chen et al. 2008, Siddiqui et al. 2010, though much weaker affinities have been reported, Koehnke et al. 2010). For β -neurexins, binding is weakest when the site B insert and SS#4 are present simultaneously and binding between β neurexins and neuroligins is not affected by Site A (Boucard et al. 2005, Ko et al. 2009a, Siddiqui et al. 2010). For α -neurexins, however, SS#4 in n1 α reduces binding to NL1, as it does for n1 β , but the Site B insert in NL1 completely disrupts binding to n1 α , unlike to n1 β (Boucard et al. 2005, Ko et al. 2009a, Reissner et al. 2008, Siddiqui et al. 2010). Furthermore, Site A seems to promote binding between n1a and NL1 (Boucard et al. 2005), a curious result given the large distance between Site A and the L6:neuroligin interface. The n1a crystal structure suggests the following insights. Firstly, Site B is located at the L6:neuroligin interface, near the hinge between L5 and EGF-C (Fig. 6). The B site insert, which also carries an N-linked glycosylation site, likely produces steric hindrance when

brought in proximity with the $n1\alpha$ specific L2–L5 assembly. Indeed, enzymatic deglycosylation of NL1 (A+, B+) largely restores its binding to n1a and this activation through deglycosylation requires the Site B insert to be present (Boucard et al. 2005). Site B and its N-linked glycosylation site are believed to be functionally important, because deletion of this glycosylation site shifts NL1 (A+, B+ N³⁰³A) to GABA-ergic synapses (Chih et al. 2006), potentially because binding to n1a splice forms at inhibitory synapses is now more viable. Secondly, our n1a:NL1 model suggests that n1a-specific modules can interact with Site A explaining why it modulates α -neurexin binding but not β -neurexin binding. While Site B has received much attention, Site A is biologically important as well. The presence of Site A inserts in NL1 (-B) and NL2 (not spliced at B) shifts these neuroligins from excitatory synapses to inhibitory synapses (Chih et al. 2006), though it must now be demonstrated that this is due to n1a-specific interactions and not other interacting proteins. Lastly, a-neurexin specific modules were shown to reduce binding to neuroligins, at least for the combinations of splice forms tested so far. Deletion mutagenesis pinpointed L3-EGF-B-L4 as the main suppressors of n1α:NL2 interaction compared to n1βmediated binding (Kang et al. 2008). If $n1\alpha$ were a linear concatenation of modules, as often depicted in the literature, these results would be difficult to explain. However, our n1a:NL1 model predicts that modules N-terminal to L6 are able to influence neuroligin binding because the extracellular domain is not linear, and L3 and/or L4 may interact directly with neuroligins (regulated by the combination of Site A and SS#3).

α-Latrotoxin—α- and β-neurexins bind α-latrotoxin in a Ca²⁺-dependent manner via L6. α-Latrotoxin binds n1α with low nanomolar affinity, competes pre-bound α-dystroglycan off, and the presence of SS#4 in n1α and n1β disrupts its binding (Davletov et al. 1995, Sugita et al. 1999). At low salt concentration (ca. 100 mM) n1β-SS#4 binds α-latrotoxin as well as n1α (+SS#1/–SS#2/+SS#3/–SS#4) (Sugita et al. 1999). However, the interaction between α-latrotoxin and n1β does not withstand a high salt concentration, unlike n1α, which still binds α-latrotoxin at unusually high salt concentrations (1.5 M NaCl) (Sugita et al. 1999). This strongly suggests that the interaction between n1β (or n1α L6) and αlatrotoxin is predominantly governed by electrostatic interactions, while additional interactions must be present in n1α that contribute hydrophobic surfaces to the interaction site with α-latrotoxin. Our n1α model suggests that not only L6, but also modules Nterminal to L6 could interact directly with α-latrotoxin because the mobility of the L5-EGF-C hinge and the spacer role of EGF-C would provide them access.

Therefore, while binding of $n1\alpha$ to neuroligins and α -latrotoxin could be described by model Fig. 5d, binding to other protein partners, for example neurexophilin binding to L2 (Missler et al. 1998) and LRRTM proteins that seem to bind $n1\alpha$ and $n1\beta$ similarly well (Siddiqui et al. 2010, de Wit et al. 2009, Ko et al. 2009a) might best be described by model Fig. 5b.

Future directions

The n1 α architecture likely impacts how many of the different α -neurexin protein partners are recruited and organized. Likewise, protein partner binding may impact the conformation of n1 α , underscoring the importance of determining structures of n1 α in complex with different ligands. The crystal structure of n1 α suggests that the modules preceding L6 may regulate the interaction of ligands bound to L6 (positively or negatively). This must now be experimentally addressed. Given that α -neurexins are increasingly implicated in neuropsychiatric diseases, it is fascinating to speculate that their lesion destroys the spatial organization of an array of synaptic proteins who are functional on their own but must be properly assembled into large macromolecular complexes to release their full potential. The strategically positioned structural elements of n1 α and a protein partner profile that can be regulated by different splice inserts distributed along its length, suggest that α -neurexins are extremely well suited to function as scaffolding molecules in the synaptic cleft and that α -neurexins may host a diverse set of protein interactions, some of which might even be targeted therapeutically in future with small molecule compounds.

Experimental Procedures

Protein expression and purification

The extracellular domain of bovine neurexin1 α (called n1 α , nm_174404) was expressed in insect cells. N1 α contains residues Met¹-Ser¹³³⁹ including the endogenous signal peptide, but not SS#1, SS#2, SS#3 or SS#4 though they are accommodated in the numbering scheme. Crystals of mutant n1 α _N190Q (no splice inserts) diffracted past 2.65Å. Crystals of n1 α +SS#3, identical to n1 α but containing SS#3 (DCIRINCNSS), diffract similarly to n1 α without the optimizing N190Q mutation. N1 α was also expressed as a seleno-methionyl form replacing 19 out of 22 methionines per molecule on average as determined by mass spectrometry.

Protein crystallization

Crystals of n1 α (native and seleno-methionyl forms), n1 α _N190Q and n1 α +SS#3 grow in a broad range of conditions containing ca. 5–10% Peg 8000 or Peg 10000, 100 mM Bicine pH 8.0–9.0, 2.5 mM CaCl₂ at 20°C, and were harvested under similar conditions containing 5 mM CaCl₂ and flash cooled with glycerol. All four proteins produce crystals with space group P1 and similar cell dimensions (for n1 α _N190Q, a=60.953 Å, b=114.543 Å, c=159.58, α =90.61 Å, β =90.87°, γ =92.18°) that are radiation sensitive and diffract weakly.

Structure determination

N1 α was solved by a combination of molecular replacement and single anomalous dispersion (SAD) techniques using PHASER (McCoy et al. 2007). Briefly, the selenomethionyl n1 α data to 4 Å was used to iteratively place 8 out of 12 possible LNS domains. Model phases generated from the partial molecular packing were then used by PHASER to locate 37 out of 44 possible selenium (Se) atoms producing a phase set with figure of merit (fom) 0.507 to 4 Å. Subsequent rounds of model building and refinement with REFMAC (Murshudov et al. 1997) generated an improved model that enabled additional Se atoms to be located by PHASER. In total, 42 potential Se sites were refined with SHARP (Bricogne et al. 2003) using the best available model phases as an external source of phase information and they produced a phase set with fom 0.678 to 3.26 Å. The model was completed and refined to 2.65 Å with the n1a_N190Q data set. Of the 40 ordered methionine residues in the $n1\alpha$ molecules, 39 match a Se atom position. Difference Fourier analysis suggests that only L2 may contain a Ca²⁺-ion. The model of $n1\alpha$ has a Molprobity Score (Chen et al. 2010) of 2.78 (66th percentile) and a clashscore of 16.45 (84th percentile); 92.2 % of the residues are in the favored region of the Ramachandran plot and 1.6 % of the residues are in the unfavorable region. The atomic coordinates of n1a_N190Q have been deposited (pdbid: 3QCW). N1 α +SS#3 was solved by molecular replacement with PHASER using the n1 α monomer as a search model (and, as a control, single LNS domains). The model of $n1\alpha$ +SS#3 refined to 2.95 Å has a Molprobity Score of 3.25 (54th percentile) and a clashscore of 25.82 (85th percentile); 89.9 % of the residues are in the favored region of the Ramachandran plot and 1.8 % of the residues are in the unfavorable region (pdbid:3R05).

Model analysis

The contact analysis was carried out using ePISA (www.ebi.ac.uk/msd-srv/prot_int/pistart.html, Krissinel & Henrick 2007).

Details of the structure determinations are summarized in Table 1 and additional details are provided in the Supplemental materials.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was funded by NIMH RO1 MH077303 and would not have been possible without funds from the American Recovery and Reinvestment Act 3R01MH077303-04S1. We thank Dr. T. Südhof for the $n1\alpha$ cDNA, Dr. D. Borek for advice on data processing, Dr. S. Anderson for excellent beam-line support, I. Wu for initial crystallization experiments and Dr. C. Brown for reagents. Diffraction data was collected at LS-CAT (beam-line 21-ID-D) at the Advanced Photon Source, Argonne National Laboratories.

References

- Araç D, Boucard AA, Őzkan E, Strop P, Newell E, Südhof TC, Brunger AT. Structures of neuroligin-1 and the neuroligin-1/neurexin-1β complex reveal specific protein:protein and protein-Ca²⁺ interactions. Neuron. 2007; 56:1–12. [PubMed: 17920006]
- Beglopoulos V, Montag-Sallaz M, Rohlmann A, Piechotta K, Ahmad M, Montag D, Missler M. Neurexophilin 3 is highly localized in cortical and cerebellar regions and is functionally important for sensorimotor gating and motor coordination. Mol Cell Biol. 2005; 25:7278–7288. [PubMed: 16055736]
- Betancur C, Sakurai T, Buxbaum JD. The emerging role of synaptic cell-adhesion pathways in the pathogenesis of autism spectrum disorders. Trends Neurosci. 2009; 32:402–412. [PubMed: 19541375]
- Blundell J, Tabuchi K, Bolliger MF, Blaiss CA, Brose N, Liu X, Südhof TC, Powell CM. Increased anxiety-like behavior in mice lacking the inhibitory synapse cell adhesion molecule neuroligin 2. Genes Brain Behav. 2009; 8:114–126. [PubMed: 19016888]
- Blundell J, Blaiss CA, Etherton MR, Espinosa F, Tabuchi K, Walz C, Bolliger MF, Südhof TC, Powell CM. Neuroligin-1 deletion results in impaired spatial memory and increased repetitive behavior. J Neurosci. 2010; 30:2115–2129. [PubMed: 20147539]
- Boucard AA, Chubykin AA, Comoletti D, Taylor P, Südhof TC. A splice code for trans-synaptic cell adhesion mediated by binding of neuroligin 1 to alpha- and beta-neurexins. Neuron. 2005; 48:229–236. [PubMed: 16242404]
- Bricogne G, Vonrhein C, Flensburg C, Schiltz M, Paciorek W. Generation, representation and flow of phase information in structure determination: recent developments in and around SHARP 2.0. Acta Cryst. 2003; D59:2023–2030.
- Chen X, Liu H, Shim AH, Focia PJ, He X. Structural basis for synaptic adhesion mediated by neuroligin-neurexin interactions. Nat Struct Mol Biol. 2008; 15:50–56. [PubMed: 18084303]
- Chen VB, Arendall WB III, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray LW, Richardson JS, Richardson DC. *MolProbity*: all-atom structure validation for macromolecular crystallography. Acta Cryst. 2010; D66:12–21.
- Chih B, Gollan L, Scheiffele P. Alternative splicing controls selective trans-synaptic interactions of the neuroligin-neurexin complex. Neuron. 2006; 51:171–178. [PubMed: 16846852]
- Chubykin AA, Atasoy D, Etherton MR, Brose N, Kavalali ET, Gibson JR, Südhof TC. Activitydependent validation of excitatory versus inhibitory synapses by neuroligin-1 versus neuroligin-2. Neuron. 2007; 54:919–931. [PubMed: 17582332]
- Collaborative Computational Project 4. The CCP4 Suite: Programs for Protein Crystallography. Acta Cryst. 1994; D50:760–763.
- Comoletti D, Flynn RE, Boucard AA, Demeler B, Schirf V, Shi J, Jennings LL, Newlin HR, Südhof TC, Taylor P. Gene selection, alternative splicing, and post-translational processing regulate neuroligin selectivity for beta-neurexins. Biochemistry. 2006; 45:12816–12827. [PubMed: 17042500]

- Comoletti D, Miller MT, Jeffries CM, Wilson J, Demeler B, Taylor P, Trewhella J, Nakagawa T. The macromolecular architecture of extracellular domain of alphaNRXN1: domain organization, flexibility, and insights into trans-synaptic disposition. Structure. 2010; 18:1044–1053. [PubMed: 20696403]
- Dahlhaus R, El-Husseini A. Altered neuroligin expression is involved in social deficits in a mouse model of the fragile X syndrome. Behav Brain Res. 2010; 208:96–110. [PubMed: 19932134]
- Davletov BA, Krasnoperov V, Hata Y, Petrenko AG, Südhof TC. High affinity binding of alphalatrotoxin to recombinant neurexin I alpha. J Biol Chem. 1995; 270:23903–23905. [PubMed: 7592578]
- de Wit J, Sylwestrak E, O'Sullivan ML, Otto S, Tiglio K, Savas JN, Yates JR 3rd, Comoletti D, Taylor P, Ghosh A. LRRTM2 interacts with Neurexin1 and regulates excitatory synapse formation. Neuron. 2009; 64:799–806. [PubMed: 20064388]
- Etherton MR, Blaiss CA, Powell CM, Südhof TC. Mouse neurexin-1alpha deletion causes correlated electrophysiological and behavioral changes consistent with cognitive impairments. Proc Natl Acad Sci USA. 2009; 106:17998–18003. [PubMed: 19822762]
- Fabrichny IP, Leone P, Sulzenbacher G, Comoletti D, Miller MT, Taylor P, Bourne Y, Marchot P. Structural analysis of the synaptic protein neuroligin and its β-neurexin complex: determinants for folding and cell adhesion. Neuron. 2007; 56:979–991. [PubMed: 18093521]
- Gibson JR, Huber KM, Südhof TC. Neuroligin-2 deletion selectively decreases inhibitory synaptic transmission originating from fast-spiking but not from somatostatin-positive interneurons. J Neurosci. 2009; 29:13883–13897. [PubMed: 19889999]
- Guilmatre A. Recurrent rearrangements in synaptic and neurodevelopmental genes and shared biologic pathways in schizophrenia, autism, and mental retardation. Arch Gen Psychiatry. 2009; 66:947– 956. [PubMed: 19736351]
- Hines RM, et al. Synaptic imbalance, stereotypies, and impaired social interactions in mice with altered neuroligin 2 expression. J Neurosci. 2008; 28:6055–6067. [PubMed: 18550748]
- Jamain S, et al. Reduced social interaction and ultrasonic communication in a mouse model of monogenic heritable autism. Proc Natl Acad Sci USA. 2008; 105:1710–1715. [PubMed: 18227507]
- Kang Y, Zhang X, Dobie F, Wu H, Craig AM. Induction of GABAergic postsynaptic differentiation by alpha-neurexins. J Biol Chem. 2008; 283:2323–2334. [PubMed: 18006501]
- Kattenstroth G, Tantalaki E, Südhof TC, Gottmann K, Missler M. Postsynaptic N-methyl-D-aspartate receptor function requires alpha-neurexins. Proc Natl Acad Sci USA. 2004; 101:2607–2612. [PubMed: 14983056]
- Knuesel I. Reelin-mediated signaling in neuropsychiatric and neurodegenerative diseases. Prog Neurobiol. 2010; 91:257–274. [PubMed: 20417248]
- Ko J, Fuccillo MV, Malenka RC, Südhof TC. LRRTM2 functions as a neurexin ligand in promoting excitatory synapse formation. Neuron. 2009a; 64:791–798. [PubMed: 20064387]
- Ko J, Zhang C, Arac D, Boucard AA, Brunger AT, Südhof TC. Neuroligin-1 performs neurexindependent and neurexin-independent functions in synapse validation. EMBO J. 2009b; 28:3244– 3255. [PubMed: 19730411]
- Koehnke J, Katsamba PS, Ahlsen G, Bahna F, Vendome J, Honig B, Shapiro L, Jin X. Splice form dependence of beta-neurexin/neuroligin binding interactions. Neuron. 2010; 67:61–74. [PubMed: 20624592]
- Krissinel E, Henrick K. Inference of macromolecular assemblies from crystalline state. J Mol Biol. 2007; 372:774–797. [PubMed: 17681537]
- Leone P, Comoletti D, Ferracci G, Conrod S, Garcia SU, Taylor P, Bourne Y, Marchot P. Structural insights into the exquisite selectivity of neurexin/neuroligin synaptic interactions. EMBO J. 2010; 29:2461–2471. [PubMed: 20543817]
- Levinson JN, El-Husseini A. Building excitatory and inhibitory synapses: balancing neuroligin partnerships. Neuron. 2005; 48:171–174. [PubMed: 16242398]
- Lo Conte L, Chothia C, Janin J. The atomic structure of protein-protein recognition sites. J Mol Biol. 1999; 285:2177–2198. [PubMed: 9925793]

- Loris R. Principles of structures of animal and plant lectins. Biochim Biophys Acta. 2002; 1572:198–208. [PubMed: 12223270]
- McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. J Appl Cryst. 2007; 40:658–674. [PubMed: 19461840]
- Missler M, Hammer RE, Südhof TC. Neurexophilin binding to alpha-neurexins. A single LNS domain functions as an independently folding ligand-binding unit. J Biol Chem. 1998; 273:34716–34723. [PubMed: 9856994]
- Missler M, Zhang W, Rohlmann A, Kattenstroth G, Hammer RE, Gottmann K, Südhof TC. Alphaneurexins couple Ca²⁺-channels to synaptic vesicle exocytosis. Nature. 2003; 423:939–948. [PubMed: 12827191]
- Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximumlikelihood method. Acta Cryst. 1997; D53:240–255.
- Nogi T, Yasui N, Hattori M, Iwasaki K, Takagi J. Structure of a signaling-competent reelin fragment revealed by X-ray crystallography and electron tomography. EMBO J. 2006; 25:3675–3683. [PubMed: 16858396]
- Reissner C, Klose M, Fairless R, Missler M. Mutational analysis of the neurexin/neuroligin complex reveals essential and regulatory components. Proc Natl Acad Sci USA. 2008; 105:15124–15129. [PubMed: 18812509]
- Rudenko G, Nguyen T, Chelliah Y, Südhof TC, Deisenhofer J. The structure of the ligand-binding domain of neurexin I beta: regulation of LNS domain function by alternative splicing. Cell. 1999; 99:93–101. [PubMed: 10520997]
- Sheckler LR, Henry L, Sugita S, Südhof TC, Rudenko G. Crystal structure of the second LNS/LG domain from neurexin 1alpha: Ca²⁺ binding and the effects of alternative splicing. J Biol Chem. 2006; 281:22896–22905. [PubMed: 16772286]
- Shen KC, Kuczynska DA, Wu IJ, Murray BH, Sheckler LR, Rudenko G. Regulation of neurexin 1beta tertiary structure and ligand binding through alternative splicing. Structure. 2008; 16:422–431. [PubMed: 18334217]
- Siddiqui TJ, Pancaroglu R, Kang Y, Rooyakkers A, Craig AM. LRRTMs and neuroligins bind neurexins with a differential code to cooperate in glutamate synapse development. J Neurosci. 2010; 30:7495–7506. [PubMed: 20519524]
- Südhof TC. Neuroligins and neurexins link synaptic function to cognitive disease. Nature. 2008; 455:903–911. [PubMed: 18923512]
- Sugita S, Khvochtev M, Südhof TC. Neurexins are functional alpha-latrotoxin receptors. Neuron. 1999; 22:489–496. [PubMed: 10197529]
- Sugita S, Saito F, Tang J, Satz J, Campbell K, Südhof TC. A stoichiometric complex of neurexins and dystroglycan in brain. J Cell Biol. 2001; 154:435–445. [PubMed: 11470830]
- Tabuchi K, Blundell J, Etherton MR, Hammer RE, Liu X, Powell CM, Südhof TC. A neuroligin-3 mutation implicated in autism increases inhibitory synaptic transmission in mice. Science. 2007; 318:71–76. [PubMed: 17823315]
- Tisi D, Talts JF, Timpl R, Hohenester E. Structure of the C-terminal laminin G-like domain pair of the laminin alpha2 chain harbouring binding sites for alpha-dystroglycan and heparin. EMBO J. 2000; 19:1432–1440. [PubMed: 10747011]
- Varoqueaux F, Aramuni G, Rawson RL, Mohrmann R, Missler M, Gottmann K, Zhang W, Südhof TC, Brose N. Neuroligins determine synapse maturation and function. Neuron. 2006; 51:741–754. [PubMed: 16982420]
- Yasui N, Nogi T, Kitao T, Nakano Y, Hattori M, Takagi J. Structure of a receptor-binding fragment of reelin and mutational analysis reveal a recognition mechanism similar to endocytic receptors. Proc Natl Acad Sci USA. 2007; 104:9988–9993. [PubMed: 17548821]
- Yasui N, Nogi T, Takagi J. Structural basis for specific recognition of reelin by its receptors. Structure. 2010; 18:320–331. [PubMed: 20223215]
- Zhang W, Rohlmann A, Sargsyan V, Aramuni G, Hammer RE, Südhof TC, Missler M. Extracellular domains of alpha-neurexins participate in regulating synaptic transmission by selectively affecting N- and P/Q-type Ca²⁺-channels. J Neurosci. 2005; 25:4330–4342. [PubMed: 15858059]

Structure. Author manuscript; available in PMC 2012 June 8.

Zhang C, Atasoy D, Araç D, Yang X, Fucillo MV, Robison AJ, Ko J, Brunger AT, Südhof TC. Neurexins physically and functionally interact with GABA(A) receptor. Neuron. 2010; 66:403– 416. [PubMed: 20471353]



Fig. 1.

N1 α structure. a) Left: n1 α is composed of 6 LNS or LG domains (laminin, neurexin, sex hormone binding globulin or laminin G domains) interspersed by three EGF-like repeats. LNS domains are indicated as grey squares labeled L1 through L6 and EGF-like repeats as black ovals labeled A, B and C. In full-length $n1\alpha$, L1 is preceded by a signal peptide and L6 is tethered to the cell membrane via a transmembrane segment (tms). Splice inserts SS#2, SS#3 and SS#4 add small stretches of amino acids to L2, L4 and L6 respectively, while SS#1 inserts a stretch of residues between EGF-A and L2. Neurexin repeats I, II, and III are indicated. Right: nomenclature of secondary structure elements in neurexin LNS domains using L2 as a template. The concave β -sheet comprises β 13, β 2, β 11, β 4, β 5, β 6, and β 7. The convex β -sheet comprises β 1, β 12, β 3, β 8, β 9 and β 10. The 'hyper-variable surface' surrounds a Ca²⁺-binding site (blue sphere) and includes loops β 2- β 3, β 4- β 5, β 6- β 7 and β 10- β 11. Some LNS domains deviate from L2 by replacing α 1 with a turn accommodated in a loop β_{12} - β_{13} or have an additional short β -strand β_{14} following β_{13} ; b) Ribbon diagram of bovine n1 α , domains L2–L6. β -Strands in neurexin LNS domains are depicted as yellow arrows, α -helices as yellow coils, loop β 11- β 12 is shown in cyan and the EGF-like repeats in magenta. The module boundaries are as follows: L2 (Glu²⁸¹-Thr⁴⁸⁵), L3 (Leu⁴⁸⁶-Cys⁶⁷⁹), EGF-B (Ser⁶⁸⁰-Glu⁷²²), L4 (Ala⁷²³-Ile⁹⁰⁹), L5 (Ile⁹¹⁰-Cys¹⁰⁸⁷), EGF-C (Glu¹⁰⁸⁸-Gly¹¹³⁰) and L6 (Thr¹¹³¹-Val¹³³⁷). An N-linked oligosaccharide chain attached to Asn¹²³⁰ is shown in ball-and-stick representation (carbon atoms, white; nitrogen atoms, blue; oxygen atoms, red).

Structure. Author manuscript; available in PMC 2012 June 8.



Fig. 2.

Neurexin repeat II (L3-EGF-B-L4). a) Variability of loop \$11-\$12 and loop \$4-\$5 in neurexin LNS domains. In a multiple structure alignment, the LNS modules superimpose in a range 1.09 to 1.37 Å for 177 to 194 Ca-atoms (see Supplemental Material). Loop B11-B12 is shown in cyan for all modules, except L6 shown in blue. Loop β 4- β 5 is shown in yellow for all modules, except L3 shown in red. The 'concave' and 'convex' β-sheets are indicated.; b) Ribbon diagram of the L3-EGF-B-L4 neurexin repeat II. Residues within 4 Å of each other forming the interfaces between modules are shown in ball-and-stick (carbon atoms, yellow, orange, cyan or magenta; oxygen atoms, red; nitrogen atoms, blue; sulfur atoms, green). Loop $\beta 11-\beta 12$ is shown in cyan, loop $\beta 4-\beta 5$ from L3 in orange. Molecular details are shown in the inset below. The insertion site for SS#3 (G⁷⁹⁰-K⁸⁰⁰) is indicated in green. Direct contacts are formed between L3 (primarily loop β 4- β 5 and loop β 11- β 12) and L4 (β 2, loop β 2- β 3, β 3, loop β 4- β 5, loop β 6- β 7, β 8, loop β 8- β 9, loop β 10- β 11, β 11 and loop β 12- α 1). Hydrophobic and charged interactions mediate the L3 and L4 interface. These include a hydrophobic cluster formed by Phe⁶³⁴, Trp⁶³⁹, Leu⁶⁴², Leu⁶⁴³ from L3 that packs against hydrophobic areas of Met⁷⁴², Thr⁷⁴⁴, Glu⁷⁴⁵, Ala⁷⁴⁶, Arg⁸²⁴ from L4, and many charged residues, in particular salt bridges between Asp⁵³⁶, Arg⁸⁴⁸, Glu⁶³⁷, Glu⁷⁴⁵ that 'zig-zag' between L3 and L4, and a striking number of histidine residues His⁵³⁹, His⁷⁴³, His⁸⁵², and His⁸⁴⁶. Direct contacts are formed between EGF-B and L3 (loop \$1-\$2, loop \$3-\$4, loop β 7- β 8, loop β 11- β 12, and the β -strands of the convex sheet β 1, β 3, and β 12, and linker residues connecting the two modules. Direct contacts are formed between EGF-B and L4 (primarily β 3, β 8, β 12, loop β 12- α 1, α 1, loop α 1- β 13) and linker residues between EGF-B and L4. Nomenclature as described in Fig. 1a. Asp⁵⁴⁶ of loop β 4- β 5 in L3, a conserved counterpart of D⁷⁷² in L4, is shown in ball-and-stick representation.; c) Ribbon diagram of the reelin repeat R6 containing modules L1, EGF, and L2 (pdb id: 3A7O, Yasui et al. 2010). L1 and L2 are shown in pink, EGF in magenta and the loop analogous to neurexin LNS domain loop $\beta 11$ - $\beta 12$ is shown in cyan for both L1 and L2. The LA1 cysteine-rich repeat of the apoE receptor 2 binds to the bottom of L1, shown in green. Calcium ions are shown as blue spheres. Reelin L2 corresponds structurally more to $n1\alpha$ L3, and reelin L1 more to $n1\alpha$ L4 when using the concave sheet filling loop $\beta 11$ - $\beta 12$ to orient the modules.



Fig. 3.

Neurexin repeat III (L5-EGF-C-L6). Residues within 4 Å of each other forming the interfaces between modules are shown in ball-and-stick. L5 and L6 are shown in light yellow, EGF-C in magenta. Loop β 11- β 12 is shown in cyan. Molecular details are shown in the inset below. EGF-C interacts with L6 by docking its C-terminal portion against the center of the convex sheet of L6 (β 3, β 8, β 9, β 12), as well as interacting with loop β 7- β 8, loop β 9- β 10, loop β 12- α 1, and the linker residues between EGF-C and L6.



Fig. 4.

Structure of n1 α +SS#3. **a**) Superposition of neurexin repeat II (L3-EGF-B-L4) without SS#3 (in grey) and carrying SS#3 (in yellow and magenta). For the latter, SS#3 is shown in green with missing residues represented by dotted lines, and loop β 4- β 5 is shown in red. For clarity, the neurexin repeat is rotated 180° with respect to Fig. 2b. b) SigmaA-weighted 2Fo –Fc electron density map in the region surrounding the splice insert SS#3, contoured at 0.9 σ for molecule 1 (left) and molecule 2 (right). In n1 α lacking SS#3, Asp⁷⁹⁰ is replaced by Gly⁷⁹⁰, and covalently connected to Lys⁸⁰⁰. Two residues have poor side chain density and have been built as alanine residues (Ile⁷⁹⁴ and Lys⁸⁰⁰). **c**) SS#3 (Asp⁷⁹⁰-Ile⁷⁹⁴, green carbon atoms) inserts between Leu⁷⁸⁹ and Lys⁸⁰⁰, and does not displace β 4- β 5 of L3 (orange carbon atoms). Residues are shown in ball-and-stick-representation with color scheme: oxygen, red; nitrogen, blue; and sulfur, yellow.



Fig. 5.

Protein partner recognition by $n1\alpha$. **a**) The hyper-variable surfaces of L2, L3, L4, L5 and L6 align on one side of $n1\alpha$ (loops shown in light orange). Conserved residues Asp³²⁹ (L2), Asp⁵⁴⁶ (L3), Asp⁷⁷² (L4), Asp⁹⁵⁸ (L5) and Asp¹¹⁸³ (L6) central to each hyper-variable surface (and in L2, L4 and L6 can ligand Ca²⁺) are shown in ball-and-stick with distances indicated. Insertion sites for splice insert SS#2, SS#3, and SS#4 are indicated with yellow, green and magenta spheres respectively. The loop $\beta4$ - $\beta5$ of L3 is shown in dark orange. Possible mechanisms by which $n1\alpha$ (L1–L6) recognizes different protein partners ('p1' – 'p6') are shown in **b**–**d**. Variability introduced by alternative splice inserts is shown for L2, L4, and L6 with carets.; **b**) single LNS domains could interact with different protein partners using splice insert dependent and/or independent mechanisms.; **c**) combinations of two LNS domains could bind protein partners potentially influenced by a splice insert.; **d**) multiple modules of $n1\alpha$ could bind a protein partner potentially influenced by one or more splice inserts.



Fig. 6.

Molecular modeling of the interaction between $n1\alpha$ and NL1. The NL1 dimer (blue) is shown with an $n1\alpha$ molecule (coloring scheme as in Fig. 5a) bound to each subunit. On the left, the $n1\alpha$:NL1 interaction is displayed as a ribbon diagram with key structural features labeled. On the right, the $n1\alpha$:NL1 interaction is shown as a ribbon diagram covered by a solvent accessible surface. Site A in NL1 is indicated by two red spheres connected by a dotted line, Site B by a single, red sphere. Splice insert sites SS#2, SS#3 and SS#4 in $n1\alpha$ are indicated by yellow, green and magenta spheres respectively. The putative hinge between L5 and EGF-C is indicated. A dotted double-headed arrow depicts potential movement of the L2–L5 assembly with respect to EGF-C-L6 controlled by the hinge.

Table 1

Data and Refinement Statistics Summary for n1a_N190Q, SMet-n1a and n1a+SS#3

| Crystal | n1a_N190Q | SMet-n1a | n1a+SS#3 |
|---|---|-------------------------|---|
| Data Statistics | | | |
| Spacegroup | P1 | P1 | P1 |
| Resolution (Å) a | 39.9-2.65 (2.70 - 2.65) | 35.0-3.25 (3.31 - 3.25) | 48.51-2.95 (3.00-2.95) |
| Reflections total/unique | 418903/124701 | 267276/67601 | 306149/89668 |
| Multiplicity | 3.4 | 4.0 | 3.4 |
| Completeness (%) | 98.5 (98.2) | 98.6 (97.9) | 98.4 (95.6) |
| R_{merge} (%) b | 7.9 (52.6) | 13.5 (80.2) | 9.0 (53.2) |
| I/σ | 17.8 (3.0) | 14.6 (1.9) | 14.1 (2.1) |
| Fom from PHASER (8 LNS domains + 37 Se atoms) to 4.0 Å: 0.507 | | | |
| Fom from SHARP (model + 42 Se atoms) to 3.26 Å: 0.678 | | | |
| Refinement Statistics | | | |
| Resolution (all reflections $ F /\sigma \geq 0.0)$ | 30.0 - 2.65 Å | | 30.0 – 2.95 Å |
| Protein atoms (including carbohydrate) | 15440 | | 15522 |
| Protein residues | 2006 (2×1003) | | 2016 (2×1008) |
| Solvent atoms | 0 | | 0 |
| Molecules in the asymmetric unit | 2 | | 2 |
| Unique reflections | 123177 | | 89495 |
| Working set/Test set c | 116726/6451 | | 84841/4654 |
| R _{work} | 20.82 % | | 20.83 % |
| R _{free} | 22.96 % | | 23.54 % |
| Rmsd bond lengths | 0.018 Å | | 0.026 Å |
| Rmsd bond angles | 1.730° | | 2.335° |
| Rmsd NCS-related molecules(C^{α} atoms) | 0.295 Å (1003) | | 0.203 Å (1008) |
| Total B_{ave} /residual B_{ave} (atoms _{mainchain}) d | 65.3 Å ² /47.2 Å ² (8024) | | 91.7 Å ² /79.4 Å ² (8064) |
| Total B_{ave} /residual B_{ave} (atoms _{sidechain}) d | 65.7 Å ² /47.9 Å ² (7360) | | 92.4 Å ² /79.8 Å ² (7402) |

^aOuter shell statistics in parentheses;

 b Rmerge= $\Sigma (|(I - \langle I \rangle)|/\Sigma (I);$

 C Test set for n1 α +SS#3 constructed using reflections present in the n1 α test set to avoid bias.

dTotal Bave reported by TLSANL/residual Bave reported after TLS and positional refinement by REFMAC